LUNAPHORE PARTNERS WITH DISCOVERY LIFE SCIENCES TO BRING INNOVATIVE SPATIAL BIOLOGY SOLUTIONS TO CLINICAL RESEARCH
Bio-Techne (NASDAQ: TECH) announced a partnership between its spatial biology brand, Lunaphore, and Discovery Life Sciences (Discovery). The collaboration aims to integrate Lunaphore's COMET™ platform into Discovery's global suite of biospecimen products and specialty lab services for clinical research.
The partnership combines COMET technology, a fully-automated, high-throughput, hyperplex platform for tissue profiling, with Discovery's scientific expertise. This collaboration is expected to advance research in immuno-oncology, immunology, neuroscience, and infectious diseases across all development stages.
Discovery's new Lunaphore COMET Hyperplex Immunofluorescence Services will support the development of next-generation assays for clinical trials and provide multidimensional spatial biology insights. The partnership aims to accelerate biomarker discovery, patient stratification, and translational medicine.
Bio-Techne (NASDAQ: TECH) ha annunciato una partnership tra il suo marchio di biologia spaziale, Lunaphore, e Discovery Life Sciences (Discovery). La collaborazione ha l'obiettivo di integrare la piattaforma COMET™ di Lunaphore nel portfolio globale di prodotti biologici e servizi di laboratorio specializzati di Discovery per la ricerca clinica.
La partnership combina la tecnologia COMET, una piattaforma hyperplex completamente automatizzata e ad alta capacità di analisi per il profiling tissutale, con l'expertise scientifica di Discovery. Si prevede che questa collaborazione possa migliorare la ricerca in immuno-oncologia, immunologia, neuroscienze e malattie infettive in tutte le fasi di sviluppo.
I nuovi servizi di Immunofluorescenza Hyperplex di Lunaphore supporteranno lo sviluppo di saggi di nuova generazione per studi clinici e forniranno informazioni di biologia spaziale multidimensionale. La partnership mira ad accelerare la scoperta di biomarker, la stratificazione dei pazienti e la medicina traslazionale.
Bio-Techne (NASDAQ: TECH) anunció una asociación entre su marca de biología espacial, Lunaphore, y Discovery Life Sciences (Discovery). La colaboración tiene como objetivo integrar la plataforma COMET™ de Lunaphore en la gama global de productos de biospecímenes y servicios de laboratorio especializados de Discovery para la investigación clínica.
La asociación combina la tecnología COMET, una plataforma hyperplex completamente automatizada y de alto rendimiento para el perfilado de tejidos, con la experiencia científica de Discovery. Se espera que esta colaboración avance la investigación en inmuno-oncología, inmunología, neurociencia y enfermedades infecciosas en todas las etapas de desarrollo.
Los nuevos Servicios de Inmunofluorescencia Hyperplex de Lunaphore apoyarán el desarrollo de ensayos de próxima generación para ensayos clínicos y proporcionarán conocimientos multidimensionales de biología espacial. La asociación tiene como objetivo acelerar el descubrimiento de biomarcadores, la estratificación de pacientes y la medicina traslacional.
Bio-Techne (NASDAQ: TECH)는 자사의 공간 생물학 브랜드인 Lunaphore와 Discovery Life Sciences (Discovery) 간의 파트너십을 발표했습니다. 이 협력의 목표는 Lunaphore의 COMET™ 플랫폼을 Discovery의 전 세계 생물 시료 제품군 및 임상 연구를 위한 전문 실험실 서비스에 통합하는 것입니다.
파트너십은 조직 프로파일링을 위한 완전 자동화된 고처리량 하이퍼플렉스 플랫폼인 COMET 기술과 Discovery의 과학적 전문성을 결합합니다. 이 협력은 면역 종양학, 면역학, 신경 과학 및 감염병 연구를 모든 개발 단계에서 발전시키는 데 기여할 것으로 예상됩니다.
Discovery의 새로운 Lunaphore COMET 하이퍼플렉스 면역형광 서비스는 임상 시험을 위한 차세대 검사의 개발을 지원하고 다차원 공간 생물학 통찰력을 제공할 것입니다. 이 파트너십은 바이오마커 발견, 환자 층화 및 전이 의학을 가속화하는 것을 목표로 합니다.
Bio-Techne (NASDAQ: TECH) a annoncé un partenariat entre sa marque de biologie spatiale, Lunaphore, et Discovery Life Sciences (Discovery). La collaboration vise à intégrer la plateforme COMET™ de Lunaphore à la suite mondiale de produits de biospecimens et de services de laboratoire spécialisés de Discovery pour la recherche clinique.
Le partenariat combine la technologie COMET, une plateforme hyperplex entièrement automatisée et à haut débit pour le profilage des tissus, avec l'expertise scientifique de Discovery. Cette collaboration devrait faire avancer la recherche en immuno-oncologie, immunologie, neurosciences et maladies infectieuses à tous les stades de développement.
Les nouveaux services d'immunofluorescence Hyperplex de Lunaphore soutiendront le développement d'essais de nouvelle génération pour les essais cliniques et fourniront des informations multidimensionnelles sur la biologie spatiale. L'objectif est d'accélérer la découverte de biomarqueurs, la stratification des patients et la médecine translationnelle.
Bio-Techne (NASDAQ: TECH) gab eine Partnerschaft zwischen seiner Marke für räumliche Biologie, Lunaphore, und Discovery Life Sciences (Discovery) bekannt. Die Zusammenarbeit zielt darauf ab, die COMET™-Plattform von Lunaphore in das globale Portfolio von Biospecimen-Produkten und spezialisierten Laborservices von Discovery für die klinische Forschung zu integrieren.
Die Partnerschaft kombiniert die COMET-Technologie, eine vollautomatisierte, hochdurchsatzfähige Hyperplex-Plattform zur Gewebeprofilierung, mit der wissenschaftlichen Expertise von Discovery. Es wird erwartet, dass diese Zusammenarbeit die Forschung in den Bereichen Immuno-Onkologie, Immunologie, Neurowissenschaften und Infektionskrankheiten in allen Entwicklungsphasen vorantreibt.
Die neuen Hyperplex-Immunfluoreszenz-Dienste von Lunaphore werden die Entwicklung von Next-Generation-Assays für klinische Studien unterstützen und multidimensionale Erkenntnisse zur räumlichen Biologie liefern. Die Partnerschaft zielt darauf ab, die Entdeckung von Biomarkern, die Patientenschichtung und die Translationale Medizin zu beschleunigen.
- Partnership expands Bio-Techne's market reach for its COMET spatial biology platform
- Collaboration enhances Discovery Life Sciences' specialty lab services offering
- Integration of COMET technology expected to advance research in multiple fields
- Partnership facilitates development of next-generation assays for clinical trials
- Potential for accelerated biomarker discovery and patient stratification
- None.
Insights
This partnership between Lunaphore and Discovery Life Sciences represents a significant advancement in spatial biology capabilities for clinical research. The integration of Lunaphore's COMET platform with Discovery's expertise has several key implications:
- Enhanced biomarker discovery and patient stratification capabilities, potentially accelerating drug development timelines
- Expansion of Bio-Techne's market reach through Discovery's global presence
- Potential for increased adoption of spatial biology techniques in clinical trials, driving demand for Bio-Techne's products
While the immediate financial impact may be , this collaboration positions Bio-Techne favorably in the growing spatial biology market. The ability to offer CLIA-compliant hyperplex tests could be particularly attractive to pharmaceutical companies, potentially leading to increased service revenues and instrument sales in the medium to long term.
Investors should monitor for future announcements regarding the uptake of these services and any resulting impact on Bio-Techne's Diagnostics & Genomics segment revenues. This partnership aligns well with the company's strategy to expand its presence in advanced research tools and could contribute to long-term growth in the spatial biology market.
MINNEAPOLIS , Sept. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that one of its spatial biology brands, Lunaphore, is partnering with Discovery Life Sciences (Discovery) to add Lunaphore COMET™, a best-in-class spatial biology platform, to Discovery's global suite of biospecimen products and specialty lab services supporting customers with clinical research.
The strategic partnership leverages Lunaphore's COMET technology, the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities, with Discovery's scientific expertise to advance immuno-oncology, immunology, neuroscience, and infectious disease research across all development stages at a new level of precision and speed. Discovery's Lunaphore COMET Hyperplex Immunofluorescence Services will facilitate the development of next-generation assays for clinical trials and provide multidimensional spatial biology insights to advance biomarker discovery, patient stratification, and translational medicine.
"We are excited to expand our specialty lab services offering to include Lunaphore COMET Hyperplex Immunofluorescence Services," said Discovery CEO Greg Herrema. "By integrating COMET with Discovery's molecular pathology expertise, this partnership is poised to drive biomedical research breakthroughs. This new service combined with our rigorous regulatory compliance processes will provide pharmaceutical companies with the ability to develop Clinical Laboratory Improvement Amendment (CLIA) compliant hyperplex tests."
"Discovery Life Sciences stands out as a pioneering global leader offering COMET's cutting-edge capabilities to biopharmaceutical clients across the
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
Contact: | David Clair, Vice President, Investor Relations & Corporate Development | |
612-656-4416 |
About Lunaphore
Lunaphore Technologies S.A. – a Bio-Techne brand, is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore's technology enables the identification of biomarker signatures with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About COMET™
Lunaphore COMET™ is the only fully-automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. The multiomics capability of COMET enables the simultaneous analysis of both RNA and protein data within the spatial context of tissues to enhance the understanding of cellular dynamics and disease processes. COMET generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. To learn more about the COMET platform, please visit: https://lunaphore.com/products/comet/
About Discovery Life Sciences
Discovery Life Sciences is a leading global provider of biospecimen products and specialty lab services. The company enables the discovery and development of therapies and diagnostics by providing pharmaceutical, biotech, and diagnostic companies with the highest quality biospecimens, in vitro preclinical solutions, and cell and gene therapy starting materials. Additionally, Discovery offers a complete suite of specialty lab services, including genomics, proteomics, molecular pathology, and cell biology, to support both prospective and retrospective clinical trials. For more information, visit dls.com.
For further information on Lunaphore:
Lindsey Rodger, Head of Communications
communications@lunaphore.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lunaphore-partners-with-discovery-life-sciences-to-bring-innovative-spatial-biology-solutions-to-clinical-research-302258200.html
SOURCE Bio-Techne Corporation
FAQ
What is the purpose of the partnership between Lunaphore and Discovery Life Sciences?
How will the Lunaphore COMET technology benefit clinical research?
What new service is Discovery Life Sciences offering as a result of this partnership?
How does this partnership align with Bio-Techne's (TECH) strategic goals?
